Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer

Background Androgen deprivation therapy (ADT) is a standard treatment for high-risk biochemically-recurrent, non-metastatic prostate cancer (BRPC) but is not curative and associated with toxicity. Racemetyrosine (SM-88) is an amino-acid analogue used with methoxsalen, phenytoin, and sirolimus (MPS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Gartrell, Benjamin A., Roach, Mack, Retter, Avi, Sokol, Gerald H., Del Priore, Giuseppe, Scher, Howard I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960617/
https://www.ncbi.nlm.nih.gov/pubmed/32924093
http://dx.doi.org/10.1007/s10637-020-00993-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960617/
https://www.ncbi.nlm.nih.gov/pubmed/32924093
http://dx.doi.org/10.1007/s10637-020-00993-4

Ejemplares similares